Stifel analyst, Paul Matteis, reiterated his Buy rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after hosting a dinner ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE